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Abstract: Although TRAIL (TNF-related apoptosis-inducing ligand, also known as Apo2L) was
described as capable of inducing apoptosis in transformed cells while sparing normal cells, limited
results obtained in clinical trials has limited its use as an anti-tumor agent. Consequently, novel TRAIL
formulations with enhanced bioactivity are necessary for overcoming resistance to conventional
soluble TRAIL (sTRAIL) exhibited by many primary tumors. Our group has generated artificial
liposomes with sTRAIL anchored on their surface (large unilamellar vesicle (LUV)-TRAIL), which
have shown a greater cytotoxic activity both in vitro and in vivo when compared to sTRAIL against
distinct hematologic and epithelial carcinoma cells. In this study, we have improved LUV-TRAIL
by loading doxorubicin (DOX) in its liposomal lumen (LUVDOX-TRAIL) in order to improve their
cytotoxic potential. LUVDOX-TRAIL killed not only to a higher extent, but also with a much faster
kinetic than LUV-TRAIL. In addition, the concerted action of the liposomal DOX and TRAIL was
specific of the liposomal DOX and was not observed when with soluble DOX. The cytotoxicity induced
by LUVDOX-TRAIL was proven to rely on two processes due to different molecular mechanisms: a
dynamin-mediated internalization of the doxorubicin-loaded particle, and the strong activation of
caspase-8 exerted by the liposomal TRAIL. Finally, greater cytotoxic activity of LUVDOX-TRAIL was
also observed in vivo in a tumor xenograft model. Therefore, we developed a novel double-edged
nanoparticle combining the cytotoxic potential of DOX and TRAIL, showing an exceptional and
remarkable synergistic effect between both agents.
Keywords: TRAIL; liposomes; cancer immunotherapy; caspase-8; doxorubicin; endocytosis
1. Introduction
TRAIL (TNF-related apoptosis-inducing ligand, also known as Apo2L) is a death ligand that
belongs to the TNF cytokine super-family. Its selective pro-apoptotic ability on transformed cells,
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leaving normal cells unaffected [1–3], sparked the interest in using this protein as a potential therapeutic
strategy in cancer [4,5]. In fact, a large number of clinical trials were carried out using TRAIL-based
therapy on a wide variety of human cancers, reaching phase II/III [6]. Unfortunately, although proven
safe, TRAIL-based therapies showed very limited therapeutic activity in clinical trials [7–9]. Therefore,
better sensitization strategies can be useful in order to overcome the resistance of cancer cells to
TRAIL [10–13]. In this line, a wide variety of drugs of different nature that can act in combination with
TRAIL, sensitizing cancer cells to apoptosis induced by this death ligand, have been described. In fact,
TRAIL has been combined, among others, with the proteasome inhibitor bortezomib [14], the cdk
inhibitor flavopiridol [15], the histone deacetylase inhibitor vorinostat [16], the flavonoid quercetin [17],
and the cytostatic drugs paclitaxel [18], actinomycin D [19], or doxorubicin [20]. On the other hand,
novel TRAIL formulations with improved bioactivity can also be of great usefulness for its future
clinical application in order to overcome TRAIL resistance [21–26]. These TRAIL formulations include
highly stable TRAIL trimers [3,27], fusion proteins with single-chain variable antibody fragments
(scFv) that active target TRAIL to cancer cells [28–31] or immune cells [32,33], mutant variants with
specificity to DR5 [34,35], and different types of nanoparticles [36–42]. In this line, our group generated
an original formulation of TRAIL based on immobilizing TRAIL molecules on the surface of artificial
lipid nanoparticles (large unilamellar vesicle (LUV)-TRAIL), resembling the natural TRAIL-containing
exosomes secreted by activated human T-cells [43,44]. We already demonstrated that LUV-TRAIL
exhibited an enhanced anti-tumor activity when compared to soluble TRAIL (sTRAIL) against leukemic
cells resistant to TRAIL or to chemotherapeutic drugs [37,45,46], and on epithelial carcinoma cells
both in vitro and in vivo [47–49]. The increased cytotoxicity of LUV-TRAIL relied on its ability to
induce an improved DR5 clustering leading to an enhanced DISC recruitment in comparison to
sTRAIL [45,49]. However, although LUV-TRAIL has proven more efficient than sTRAIL in all tumor
cell lines tested, some cancer cell lines remain somewhat resistant to its pro-apoptotic activity. Therefore,
seeking to optimize the original LUV-TRAIL formulation to overcome the resilient TRAIL-resistance
of some cancer cells, we have generated a novel liposomal formulation combining LUV-TRAIL with
a chemotherapeutic drug encapsulated inside the lipid nanoparticle. Concerning the drug to be
encapsulated, after performing a research work and considering several options among the already
described liposomal drugs, liposomal doxorubicin (DOX) was finally chosen. Liposomal DOX was one
of the first encapsulated drugs to be developed, more than 20 years ago, and its anti-tumor bioactivity
has been assessed in a great number of scientific articles (reviewed in Reference [50]). In this line,
the use of liposomal DOX assembled to the erythrocyte leveraged chemotherapy (ELeCt) platform in
cancer treatment has been recently reported [51]. In this work, the authors demonstrate that liposomal
DOX using the ELeCt platform is highly effective against lung metastasis in a melanoma model.
Doxorubicin has been described to synergize with TRAIL when administered in combination in several
studies [38,52–55]. Beyond DOX has been reported to synergize with TRAIL, its liposomal was chosen
due to scientific literature about the preparation and characterization of liposomal DOX, which can
be easily found (reviewed in Reference [56]). Moreover, from an experimental point of view, the
encapsulation protocol of DOX perfectly suited the coupling process of TRAIL with LUV, so both
processes (encapsulation and coupling) could be easily combined with minor modifications. Thus, we
devised the generation of a unique formulation combining both TRAIL and DOX (LUVDOX-TRAIL),
which could be of great interest to overcome the resistance of different types of cancer. Therefore, we
used the liposomal particle of LUV-TRAIL as a vehicle for DOX, resembling the well-known liposomal
formulation of DOX, but combining it with the superior pro-apoptotic potential of LUV-TRAIL,
generating LUVDOX-TRAIL. This double-edged new formulation can potently and simultaneously
trigger the intrinsic and the extrinsic apoptotic pathways to induce a great cytotoxic effect against
tumor cells. Indeed, this new liposomal formulation exhibited an outstanding pro-apoptotic potential,
greatly improving the performance of LUV-TRAIL in all cancer cells tested. It is noteworthy that
LUVDOX-TRAIL was capable of overcoming the resistance to LUV-TRAIL in highly TRAIL-resistant
cancer lines. Moreover, LUVDOX-TRAIL with a defined low concentration of DOX maintained their
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greater anti-tumor effect both in vitro and in vivo while sparing normal cells. Our results show that
this optimized double-edged LUV-TRAIL formulation harbors an enhanced exceptional cytotoxic
ability and could be potentially useful to improve anti-tumor therapy against TRAIL-resistant cancers.
2. Results
2.1. Synthesis and Characterization of Large Unilamellar Vesicle Doxorubicin-TNF-Related Apoptosis-Inducing
Ligand (LUVDOX-TRAIL)
Large unilamellar vesicles (LUVs) encapsulating DOX inside their lumen and decorated with
TRAIL on their surface (LUVDOX-TRAIL (LDT)) (Figure 1a) were synthetized as outlined in the
protocol shown in Figure 1b. DOX was encapsulated inside the liposomal lumen using the pH
gradient method, as described in the Material and Methods Section. In short, this method relies on the
generation of a pH difference between the liposomal lumen (low pH) and the external media (neutral
pH). Thus, DOX molecules passively diffuse from the media to the liposomal lumen, where the low pH
induces a protonation of the DOX molecule, rendering it insoluble and therefore unable to cross the
lipid barrier, being entrapped inside the liposomes. As shown in Figure 1d, this method rendered an
entrapment efficiency of around 97%. Assuming this encapsulation efficiency, the final concentration
of encapsulated DOX was 1.4 mM (Figure 1c). In contrast, as expected, classic LUVs bearing PBS in the
liposomal lumen (LUV-PBS) showed a rather poor encapsulation efficiency. Cryo-TEM assessment
confirmed the presence of a homogeneous population of liposomal particles of around 100 nm of
diameter, similarly to LUV-TRAIL (LT) [57]. Of note, a black aggregate inside the liposomes could also
be observed, corresponding to the precipitated insoluble DOX, which is a typical feature of liposomal
DOX encapsulation (Figure 1e).
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Figure 1. (a) Schematic representation of large unilamellar vesicle doxorubicin-TNF-related 
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(DOX) was measured. The DOX standard curve was used to interpolate the results obtained in (d). 
(d) Encapsulation efficiency and release profile of doxorubicin in LUV-AS. DOX was incubated with 
LUV-AS at a molar ratio of 1:3.8 (drug:lipid) for 30 min at 60 °C. At the indicated times, samples were 
taken and free DOX was separated from the liposomal fraction. Encapsulated DOX was quantified by 
Figure 1. (a) Schematic representation of large unilamellar vesicle doxorubicin-TNF-related
apoptosis-inducing ligand (LUVDOX-TRAIL (LDT)). (b) Schematic illustration of the generation
of LDT. Generation of LDT was performed as describe in the Experimental Section. (c) Standard curve
of doxorubicin concentration. Absorbance at 480 nm of the indicated concentrations of doxorubicin
(DOX) was measured. The DOX standard curve was used to interpolate the results obtained in (d).
(d) Encapsulation efficiency and release profile of doxorubicin in LUV-AS. DOX was incubated with
LUV-AS at a molar ratio of 1:3.8 (drug:lipid) for 30 min at 60 ◦C. At the indicated times, samples were
taken and free DOX was separated from the liposomal fraction. Encapsulated DOX was quantified by
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measurement of absorbance at 480 nm. Efficiency is represented as percentage of total doxorubicin
present in the liposomal fraction in every time point. (e) Scanning electron microscopy of LDT was
carried out as described in the Experimental Section. Original magnification was 45,000×. (f) Coupling
efficiency of soluble TRAIL in the LDT formulation. Once LUVDOX-TRAIL were generated, they were
ultra-centrifuged at 60,000 rpm for 5 h, collecting the supernatant and resuspending the pellet. Aliquots
from the pellet and the supernatant fractions were separated by SDS-PAGE and the presence of TRAIL
in both fractions was assessed by Western blot.
Once the feasibility and efficiency of the DOX encapsulation method were proven, the next step
was to attach sTRAIL on their surface. For that, sTRAIL was incubated with LUVDOX (LD) at the
same protein/lipid ratio as in the classic LT [37] to obtain the LDT formulation. Importantly, sTRAIL
was coupled to LD by incubating at 15 ◦C instead of the classic 37 ◦C used for LT to diminish possible
leakage of DOX. However, this lower incubation temperature did not compromise sTRAIL attachment
to the liposomal surface. As shown in Figure 1f, the coupling efficiency was very high and similar to
that of classic LT [57], validating the modification of the protocol. Therefore, the final concentration of
DOX and TRAIL within LDT was 775 µM and 12 µg/mL, respectively.
2.2. In Vitro Cytotoxic Potential of LUVDOX-TRAIL
The anti-tumor activity of LDT was tested on a panel of cell lines, composed mainly by
TRAIL-resistant cell lines (Supplementary Figure S1). As shown in Figure 2, LDT showed an exceptional
cytotoxic activity on all cell lines tested, proving more efficiency than LT and LD, respectively. In this
regard, although LD alone induced some cytotoxicity on some cell lines, this was rather limited in
most cases (Figure 2a). The cells presented the typical features of apoptotic cell death, such as blebbing
and cell shrinkage. Importantly, the effect of LDT was not observed when LT was co-administered
in combination with increasing concentrations of soluble DOX up to more than 15-fold that of LDT
(Figure 2c), suggesting a specific synergism between the liposomal DOX and liposome-bound TRAIL.
Next, we measured the killing kinetic of LDT. As shown in Figure 2d, LDT showed a much faster
cytotoxic kinetic than both LD and LT. In all epithelial cancer cell lines, LDT reached the maximum
cell death after six hours (Figure 2d, upper panels). Moreover, in A549 and SKBR3 cells, the onset
of cell death could be observed already after two hours. On the other hand, LDT showed a slower
kinetic on sarcoma cell lines, reaching maximum levels at 20 hours (Figure 2d, bottom panels). In all
cases, LD only showed a limited cytotoxic exposure effect, with LDT being significantly more potent in
all cases. Altogether, our results show a unique synergistic effect between the surface-bound TRAIL
and the encapsulated DOX, which cannot be achieved by LT, LD, or an equivalent concentration of
soluble DOX.
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A549, HT-29, SKBR3, and MDA-MB-468 cells were treated with LUV-TRAIL (LT), LUVDOX (LD), or
LDT (TRAIL at 1 µg/mL) for 24 h. Bright field microscopy images of the Control, and cells treated
with LD and LDT, were taken. Original magnification was 200×. (b) A panel of tumor cell lines (A549,
HT-29, SKBR3, MDA-MB-468, A673, HT-1080, Raji, RD, U937, and MOLT4) were treated with increasing
concentrations of LT, LD, or LDT for 24 h. The following day, cell death was measur d by annexin-V
staining. Graphs show the mean ± standard deviation (SD) f at least three in ependent experiments.
* p < 0.05, ** p < 0.01, *** p < 0.001. (c) Combined treatment of LT with increasing concentrations
of solubl DOX on A549 cells. A549 cells were treated with LT (1000 ng/mL) in combination with
increasing c centrations of soluble DOX for 3 h. Besides, LDT was also used as a reference. Results are
the mean ± SD of three independent experiments. (d) Time-course cytotoxicity of LDT on the tumor
cell c lls: A549, SKBR3, HT-29, A673, HT-1080, a RD cells. Cells were treated with LD or LDT at their
maximum concentrations (1 µg/mL TRAIL; 64.56 µM DOX) for the indicated times. Apoptotic cells
ere measured by annexin-V staining. Graphs show the mean ± SD of four different experiments.
* p < 0.05, ** p < 0.01, LT versus LDT # p < 0.05, ## p < 0.01, ### p < 0.001 LD versus LDT.
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2.3. LUVDOX-TRAIL are able to Induce a Stronger Activation of the Extrinsic Apoptotic Pathway than
LUV-TRAIL in Cancer Cells
Next, we set out to characterize the nature of the cell death induced by LDT. First, the role of TRAIL
in the cytotoxicity exerted by LDT was analyzed by blocking TRAIL (Figure 3a). Pre-incubation with the
TRAIL-blocking antibody RIK completely protected all cell lines from LDT-induced cytotoxicity. On the
other hand, the exposure of phosphatidylserine detected by annexin-V staining in the cytotoxicity
experiments suggested a classic apoptotic process. To corroborate that, the role of caspases in LDT
was explored. First, sarcoma cell lines HT-1080 and RD were incubated with sTRAIL, LT, LD, and
LDT for 20 hours and activation of the main caspases involved in the extrinsic apoptotic pathway was
assessed by Western blot (Figure 3b, upper panels). Activation of caspase-8 and caspase-3 was clearly
increased when sarcoma cells were treated with LT compared to sTRAIL, as previously described [58].
Moreover, cleavage of Bid and PARP-1, the specific substrates for caspases-8 and -3 respectively,
correlated with the activation of both caspases. It is noteworthy that LD had no effect on caspase
activation. In contrast, LDT induced a stronger caspase activation than both LD and LT, which
correlated with a higher cell death induction in the same experiments (Figure 3b, bottom panels).
When analyzed in a time-course setting, LDT again showed a much faster ability to activate caspases -8
and -3 (Figure 3c). It is worth noting that LDT also induced a quick and strong activation of caspase-9.
Overall, while LD did not induce any noticeable activation of any of the three caspases analyzed,
LDT induced a clear and strong activation of the three caspases even from the 30-minute time point.
Interestingly, the three caspases seemed to be activated simultaneously. With that aim, analysis of
caspase activation after pre-incubation with the pan-caspase inhibitor z-VAD-fmk was carried out in
sarcoma cells (Figure 3d). Treatment with z-VAD-fmk abrogated caspase activation almost completely
both in HT-1080 and RD cells treated with LT and with LDT. Moreover, cleavage of Bid and PARP-1,
the specific substrates for caspases-8 and -3 respectively, were also fully inhibited when cells were
treated with z-VAD-fmk. Having corroborated that LDT induced a strong caspase activation, we next
checked if caspases were the main driver of LDT cytotoxicity. Thus, A549, SKBR3, and HT-29 cells
were subjected to LDT treatment, in the presence or absence of the pan-caspase inhibitor z-VAD-fmk
or the specific caspase-8 inhibitor z-IETD-fmk (Figure 3e). Both caspase inhibitors were able to revert
cell death almost completely. All the results pointed towards LDT-induced apoptosis being a purely
caspase-8-dependent process. In order to corroborate the role of caspase-8, the rhabdomyosarcoma cell
line RH4, which is known to lack caspase-8 [59], was also studied. LDT did not have any cytotoxic
effect on RH4 cells (Supplementary Figure S2a), therefore corroborating the main role ofcaspase-8
in LDT-induced apoptosis. In this line, silencing caspase-8 in SKBR3 cells completely abrogated
LDT-induced cell death (Supplementary Figure S2b). Finally, given the double-edged nature of LDT,
being a priori able to trigger both the extrinsic and the intrinsic apoptotic pathways, and considering
the strong activation of caspase-9 observed in Figure 3c, we also checked the activation of the intrinsic
apoptotic pathway by using modified HCT-116 cells lacking both Bax and Bak (HCT-116 BB), therefore
lacking a functional mitochondrial apoptotic pathway [49] (Supplementary Figure S2c). HTC-116 BB
cells were completely resistant to LDT, suggesting an important role for the mitochondrial apoptotic
pathway in LDT-induced cell death.
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Figure 3. (a) Roles of DOX and TRAIL in LUVDOX-TRAIL (LDT) cytotoxicity. A549, SKBR3, and
HT-29 cells were treated with the indicated combinations of LUV-TRAIL (LT), LUVDOX (LD), and
LDT (TRAIL at 1000 ng/mL). When indicated, cells were pre-treated with the TRAIL-blocking antibody
RIK. Cell death was assessed by annexin-V staining after 6 h of trea ment. Graphs show the mean ±
SD of at least four experiments. *** p < 0.001. (b) An lysis of caspase activation after treatment with
different TRAIL versions. HT-1080 and RD cells were untreated (Control, designed as C), or treated
with soluble TRAIL (ST), LT, LD, and LDT at 1000 ng/mL. After 24 h, cells wer lysed, and lysates
were subject d to SDS-PAGE and to Western blot analysis Levels of caspase-8, caspase-3, Bid, and
PARP-1 were analyzed using specific antibodies. The evel of actin levels was used a control for
equal protein lo ding. Cell death was quantified in para lel by flow cytometry after annexin-V staining
(bottom pan ls). (c) Analysis of time-course c spase activation with LD or LDT. A549 cells were treated
with LD or LDT (1 µg/mL TRAIL; 64.56 µM DOX) at the indicated times. Finally, cells were lysed, and
lysat s wer subjected to S S-PAGE and to Western blot analysis. (d) A alysis of caspase ctivation
after treatment with different TRAIL versions. HT-1080 and RD cell were untreated (Control, designed
as C), or treated with LUV alone (CL), LT, LD, and LDT at 1000 ng/mL. When indicated, cells were
pre- with he pan-caspase inhibitor z-VAD-fmk (30 µM). After 24 h, cells were lysed, and lysates
were subjected to SDS-PAGE and to Western blot analysis. Levels f caspase-8, caspase-3, Bid, and
PARP-1 analyzed using specific antibodies. Actin levels was used as a control for equal protein
lo ding. (e) Role of caspases in LDT cytotoxicity. A549, SKBR3, and HT-29 c lls were treated with LT,
LD, or LDT (TRAIL t 1000 ng/mL). Wh n indicated, cells were pre-treated either with the pan-caspase
inhibitor z-VAD-fmk (30 µM) or with the specific caspase-8 inhibitor z-IETD-fmk (30 µM) for 1 hour.
Cell d ath was assessed by nexin-V staining after 6 h of treatment. Graphs show the mean ± SD of at
least four experiments. * p < 0.05, ** p < 0.01, *** p < 0.001.
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2.4. LUVDOX-TRAIL-Induced Cytotoxicity is a Dynamin-Dependent Mechanism Involving Caspase-8 Activity
Although the involvement of TRAIL in LDT cytotoxicity was clear, the contribution of DOX to the
cell death was still elusive. Indeed, the uptake mechanism of LD and LDT was still unclear. To perform
a more detailed analysis of the role of DOX in both liposomal formulations (LD and LDT), A549 cells
were subjected to time-course stimulation with both liposomal formulations, and DOX fluorescence
was analyzed by microscopy. As shown in Figure 4a, both LD and LDT could be readily detected
inside the cells already after 15 minutes of treatment. This fluorescence remained mostly unchanged
for LD, whereas in LDT-treated cells, the red fluorescence pattern dramatically changed, adopting a
very condensed aspect over time, and localizing in what could be identified as the nucleus. It is worth
noting that no apoptosis could be detected in LD-treated cells, correlating with our previous results.
In addition, the sharp DOX condensation only occurred in cells undergoing apoptosis (white arrows in
T = 120), suggesting a cause–effect correlation between apoptosis and DOX localization in the nucleus.
Interestingly, the fluorescence pattern observed for both LD and LDT at short times appeared
to localize in a somehow defined cellular compartment, rather than being dispersed in the cytosol
(T = 15). Having proven that encapsulated DOX both in LD and LDT was endocytosed, and taking
into consideration previous studies reporting the lysosomal localization of DOX after treatment with
liposomal doxorubicin [60], we considered the possibility of DOX being localized in the endosomal
compartment. To corroborate this, a specific lysosomal marker (Lysotracker™) was used in parallel to
LD or LDT administration (Figure 4b). After 60 minutes of exposure, almost all DOX fluorescence
co-localized with Lysotracker™ in A549 cells treated with LD. However, when treated with LDT, most
of DOX fluorescence already seemed to be located at the nucleus, whilst only a faint red fluorescence
could be observed outside the nucleus, seemingly co-localizing with the lysosomal tracker, suggesting
that at least part of the DOX would still remain in the lysosomes.
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Figure 4. (a) Fluorescence microscopy of A549 upon treatment with LD or LDT. A549 cells were 
treated with LD or LDL at their maximum working concentrations (1 μg/mL TRAIL; 64.56 μM DOX) 
at the indicated times. At the final time, medium was carefully replaced, and cells were cooled for 10 
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Figure 4. (a) Fluorescence microscopy of A549 upon treatment with LD or LDT. A549 cells were treated
with LD or LDL at their maximum working concentrations (1 µg/mL TRAIL; 64.56 µM DOX) at the
indicated times. At the final time, medium was carefully replaced, and cells were cooled for 10 minutes
at 4 ◦C. Finally, bright field and red fluorescence pictures were taken by fluorescence microscopy.
(b) Subcellular location of LD and LDT. A549 cells were pre-treated for 1 h with Lysotracker™. Then,
cells were treated with LD or LUVDOX-TRAIL (TRAIL, 1000 ng/mL TRAIL) for 1 h. At the final time,
medium was replaced, and cells were cooled for 10 min at 4 ◦C. Finally, green and red fluorescence
pictures were taken by fluorescence microscopy. Original magnification was 400×. (c) Inhibitory effect
of dynasore on cell death and DOX fluorescence of upon treatment with LD or LDT. A549 and SKBR3
cells were treated with LD or LDT for 3 h. In some cases, cells were pre-treated with dynasore (DYN,
80 µM) for 1 h. Cell death was measured by annexin-V staining and DOX uptake was quantified
by red-fluorescence measurement, respectively. Graphs show the mean ± SD of four independent
experiments. * p < 0.05, ** p < 0.01, *** p < 0.001. (d) Confocal microscopy of A549 upon treat ent
with LD or LDT. A549 cells were treated with LD or LDL at their maximum working concentrations
(1 µg/mL TRAIL; 64.56 µM DOX) at the indicated times. In some cases, cells were pre-treated with
dynasore (DYN, 80 µM) or z-VAD-fmk (zVAD, 30 µM) for 1 hour. Cells were stai ed with antibody
anti-LAMP-1 and the probe DAPI. At the final time, mediu was carefully replaced, and cells wer
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cooled for 10 minutes at 4 ◦C. Finally, fluorescence pictures were taken by confocal microscopy.
(e) Analysis of the time-course activation of caspases after treatment with LT, LD, and LDT. A549 cells
were treated with LT, LD, and LDT at 1000 ng/mL. When indicated, cells were pre-treated either with
DYN (80 µM) or z-VAD-fmk (30 µM). After, cells were lysed, and lysates were subjected to SDS-PAGE
and to Western blot analysis. Levels of caspase-8, caspase-9, caspase-3, and PARP-1 were analyzed
using specific antibodies. Level of actin was used as a control for equal protein loading. (f) Effect of
combined treatment of LD and LUV-TRAIL on cell-death and DOX-fluorescence. Tumor cells were
treated with LD and LUV-TRAIL alone, or with the combination of both LD and LUV-TRAIL for 3 h.
Besides, LDT was used in parallel as a reference. In some cases, cells were pre-treated with dynasore
(DYN, 80 µM) or z-IETD-fmk (zIETD, 30 µM) for 1 hour. (e) Cell death was measured by annexin-V
staining and (f) DOX uptake was quantified by red-fluorescence measurement, respectively. Graphs
show the mean ± SD of five independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001.
Next, we characterized the involvement of the endocytic pathway in LD- and/or LDT-induced
cell death using the specific dynamin inhibitor Dynasore (DYN) [61]. A549 and SKBR3 cells were
pre-treated with DYN for one hour prior to the addition of LD or LDT and apoptosis induction was
measured at three hours to analyze the early cell death induced by LDT (Figure 4c). Of note, DOX
uptake by the cells was also assessed by measuring its characteristic red fluorescence by flow cytometry.
In the absence of DYN, cytotoxicity perfectly correlated with previous data. When cells were pre-treated
with DYN, cell death induced by LDT was abrogated in both cell lines. Regarding DOX fluorescence,
in general, both LD and LDT presented high MFI levels in both cell lines, although fluorescence was
slightly higher for LDT. Interestingly, similarly to apoptosis levels, fluorescence levels were significantly
reduced by DYN. All of this data strongly suggested a role for dynamin in the uptake of the liposomal
DOX into the lysosomal compartment, regardless of the presence of TRAIL on the liposomal surface
and proved that DOX requires to be internalized in order to exert its cytotoxicity. A deeper analysis by
confocal microscopy in A549 cells following a time-course treatment with either LD or LDT further
corroborated these observations (Figure 4d). Thus, while DOX could be readily detected colocalizing
with the lysosomal marker LAMP-1 already after 5 minutes of stimulation with LDT, DOX could only
be clearly detected after 30 minutes of stimulation in the case of LD. Moreover, in LDT-treated cells,
DOX fluorescence co-localized with DAPI already after 15 minutes, and almost all DOX was present
inside the nuclei after 30 minutes. In the case of LD, the uptake was much slower, with DOX only
beginning to be clearly detected inside the cells after 30 minutes, and overall to a lesser extent than LDT.
Remarkably, when A549 cells were pre-treated with DYN, co-localization of DOX with DAPI
was dramatically decreased both in LD-treated and LDT-treated cells. Interestingly, pre-treatment
with z-VAD-fmk also decreased the amount of DOX into the nuclei, although to a lesser extent than
DYN. When analyzed by Western blot, LT and LDT showed a clear activation of the caspase cascade,
although LDT again showed a more robust activation and cleavage of all caspases and substrates
analyzed (Figure 4e). LD did not induce any activation of any caspase, including caspase-9. As expected,
caspase activation was reduced after z-VAD-fmk treatment. Interestingly, pre-treatment with DYN
also diminished caspase activation.
Finally, we wanted to assess whether LT administered in combination with LD should render
a similar outcome to LDT. For that, experiments using LD along with LT were carried out on A549
and SKBR3 cells, comparing with LDT. To dissect the roles of the endocytic process on the one hand
and of TRAIL-induced caspase-8 activation on the other, cells were pre-treated with DYN and with
z-IETD-fmk, and both apoptosis induction and DOX fluorescence were measured (Figure 4f). LDT was
again the most cytotoxic agent. Interestingly, the combination of LD and LT showed a substantial
synergy to induce cell death in both cell lines. Importantly, both DYN and z-IETD-fmk were able
to abrogate apoptosis induced by LDT or by the combination of LT and LD. Regarding intracellular
fluorescence, the result was similar to that observed in Figure 4a, where LD and LDT showed similar
fluorescence patterns. In this case, the combination of LD and LT rendered similar results to LD alone
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or LDT. Moreover, the dynamin inhibitor DYN not only blocked DOX fluorescence upon treatment
with LD or LDT, but also with the combination of LT and LD. Remarkably, the caspase-8 inhibitor
z-IETD-fmk significantly reduced DOX fluorescence levels in the points where TRAIL was involved,
indicating that DOX fluorescence intensity was also dependent of caspase-8 activity.
2.5. Reduction of DOX Concentration in LUVDOX-TRAIL Reduces Their Toxicity on Normal Peripheral Blood
Mononuclear Cells (PBMC) but Maintain Cytotoxicity on Cancer Cells
After assessing the greater cytotoxic effect of LDT in all cancer cell lines tested, and having
characterized its mechanism of action, we next sought to test the possible cytotoxicity of this new
formulation on normal primary cells. For that purpose, cytotoxicity of LDT was analyzed on freshly
isolated peripheral blood mononuclear cells (PBMC) and on activated T-cells (or T-cell blasts) generated
from those PBMC (Supplementary Figure S3). LDT induced cell death on PBMC and on day-6 T-cell
blasts after 24 hours of treatment when used at the usual concentrations of DOX and TRAIL (64 µM of
DOX and 1 µg/mL of TRAIL, respectively) (Supplementary Figure S3a,b). Toxicity was similar on both
CD4+ and CD8+ 6-day T-cell blasts subpopulations (Figure S3c,d), and it was clearly due to DOX, since
LD exhibited a similar cytotoxicity pattern. In order to decrease LDT toxicity on normal cells, LDT
with a concentration of DOX 10 times lower than those previously described (hereafter LDT 1/10) but
with the same concentration of TRAIL were generated. Reduction of the concentration of encapsulated
DOX to 6.4 µM eliminated the toxicity of LDT on freshly isolated PBMCs and considerably reduced
the cytotoxicity on 6-day T-cell blasts (Supplementary Figure S3a,b). Finally, the cytotoxic potential of
LDT 1/10 was assessed, as in Figure 2, using the same cell lines (Figure 5). Reduction of encapsulated
DOX in liposomal composition reduced the cytotoxic potential of LD and LDT. However, although
slightly reduced, importantly, LDT 1/10 still retained a strong activity against all cancer lines tested,
still being the most potent formulation (Figure 5).
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** p < 0.01, *** p < 0.001. (b) Cytotoxicity of LDT 1/10 on a panel of tumor cell lines from distinct
origin. Raji, U937, and MOLT-4 cells were treated with LT, LD 1/10, or LDT 1/10 for 24 h. Bright
field microscopy images of the Control, and cells treated with LD and LDT, were taken. Original
magnification was 200×. (c) Comparison of LDT and LDT 1/10 on a panel of tumor cell lines from
distinct origin. A panel of tumor cell lines (A549, HT-29, SKBR3, A673, HT-1080, Raji, RD, U937, and
MOLT4) were treated with LT, LDT, and LDT 1/10 with different entrapped DOX concentrations (LDT:
DOX at 64.56 µM or LDT 1/10: DOX at 6.45 µM). The final concentration of TRAIL was 1000 ng/mL in
all cases. After 24 h, cell death was quantified by annexin-V staining. Graphs show the mean ± SD of at
least three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001.
2.6. In Vivo Cytotoxic Potential of LUVDOX-TRAIL
Next, we sought to assess the in vivo efficiency of LDT. However, and given the high cytotoxicity
of LDT in vitro, we first checked the safety of LDT, to rule out any overt adverse effect in vivo. Thus,
both LT and LDT were systemically injected in mice. No sign of inflammatory infiltrate, fibrosis, or
necrosis in any tissue were observed (Figure 6a). Moreover, there was no increase in ALT or AST
serum levels after treatment with LDT, excluding in vivo hepatotoxicity, a well-known adverse effect
described for TRAIL (Figure 6b) [62]. Therefore, we could conclude that LDT do not present systemic
toxicity, and they can be used as a therapeutic agent in vivo.
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Figure 6. (a) Histological analysis of different tissues derived from LUV-DOX-TRAIL 1/10-treated mice.
Mice were subjected to systemic LUVDOX-TRAIL 1/10 (LDT 1/10) treatment 4 times with an interv l of
2 days. After that, organs were surgically dissected and fixed in 10% buffered formalin. Aft r fixatio
for 3 d ys, tissues were embedded in paraffin and sectioned in 5 µm sections. The slides
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were then deparafined in xylene, dehydrated in a gradient of alcohols, and stained using hematoxylin
and eosin (H and E). Original magnification was at 100× and 200×. (b) Determination of serum
levels of AST and ALT in LDT 1/10-treated mice. Mice were subjected to systemic LUV-TRAIL
treatment 4 times with an interval of 2 days. After that, mice were sacrificed, and blood samples
were collected by heart puncture. Blood samples were then centrifuged to obtain serum, and AST
and ALT levels were analyzed in the obtained serum samples by nephelometry. Graphics represent
the results as a dot plot of the data collected from 4 mice in the LDT 1/10 group and 2 mice in the
control group. (c) Mice bearing HT-1080 tumors received intra-peritoneal injections of PBS, LUV-TRAIL
(LT, 36 µg of TRAIL/injection), or LUVDOX-TRAIL 1/10 (LDT 1/10, 36 µg of TRAIL/injection) for
4 days (arrow-pointed). Percent survival of mice from the control, LT, and LDT 1/10 groups was
monitored for 20 days. Results are expressed as a Kaplan-Meier graphic. (d) In vivo anti-tumor activity
of LUV-TRAIL and LUVDOX-TRAIL 1/10. Mice bearing HT-1080 tumors received intra-peritoneal
injections of PBS, LUV-TRAIL (LT, 36 µg of TRAIL/injection), or LUVDOX-TRAIL 1/10 (LDT 1/10,
36 µg of TRAIL /injection) for 4 days (arrow-pointed). Tumor growth is depicted, calculated using the
formula: tumor volume = L ×W ×H (where L is length, W is width, and H is the height dimensions of
the tumor respectively). (e) Time-course analysis of the tumor growth in mice bearing HT-1080 tumors.
Tumor volumes corresponding to 25%, 50%, and 75% respectively, of the final volume at the moment of
the sacrifice in every group were calculated. Time (in days) at which tumors reached these volumes in
every group was calculated and expressed as dot plot of animals in each group. * p < 0.05, ** p < 0.01.
Next, we tested the efficacy of LDT on a subcutaneous xenograft model. Thus, Hsd:Athymic
Nude-Foxn1nu mice bearing subcutaneous HT-1080 tumors were treated intraperitoneally with daily
injections of either LT or LDT 1/10 for four consecutive days (described in the Materials and Methods
Section). Tumor volumes were monitored, and mice were culled when the tumor volume reached
100 mm2. All control mice were culled at day 13, while mice treated with LT survived until day 18.
In the case of mice treated with LDT, 66.7% (4 animals of 6 included in this group) survived until
day 20 (Figure 6c). Mice treated with LT showed a slower tumor growth, whilst mice treated with
LDT showed a marked growth delay (Figure 6d). To corroborate the delay in tumor growth, the time
average that the tumors took to reach the 25%, 50%, and 75% of the final volume at the moment of
the sacrifice in every group was analyzed (Figure 6e). Although no differences were observed in the
time average at which the control and LT groups reached the 25% and 50% of the tumor growth,
mice treated with LT presented a significant delay in the time they took to reach 75% of the tumor
growth when compared to the control group. On the other hand, tumors of mice treated with LDT
took significantly longer to reach 25%, 50%, and 75% of the tumor volume when compared to both the
control and LT groups.
3. Discussion
TRAIL-based therapies in cancer exhibited very limited therapeutic activity in clinical trials [6–9],
therefore, novel TRAIL formulations with improved bioactivity that can overcome TRAIL resistance
would be of utility as cancer treatment [21–26]. In this regard, we have demonstrated in the present
study that LDT exhibited a greatly improved cytotoxicity against a broad panel of cancer cells from
distinct origins, overcoming resistance to sTRAIL or to LT, while LD alone did not show a remarkable
cytotoxic effect in the case of epithelial cells, in which cytotoxicity was dependent on the presence of
TRAIL. In the case of sarcoma cells, LD contributed to the cytotoxic effect, but the presence of TRAIL
enhanced cytotoxicity even more. Finally, in hematological cancer cell lines, with the exception of
MOLT4 cells, in which the greater cytotoxicity observed with LDT seemed to be attributable rather to
DOX, cytotoxicity was due to the combination of TRAIL and DOX. In any case, the use of TRAIL and
DOX in a unique formulation such as LDT exhibited an enhanced cytotoxic effect when compared to
LT or LD alone on all cell lines tested, overcoming the resistance to sTRAIL. In this line, soluble DOX
has been long described to synergize with sTRAIL when administered in combination [53–55,63,64].
However, this synergy happened at minimum incubation times of at least 12 hours, while the effect
observed with LDT happened in a much shorter time frame. Moreover, a synergistic effect of LT with
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soluble DOX at 64.56 µM cannot be achieved. However, the effective amount of DOX that would
actually get inside the cells when liposomal DOX was used might be much higher. In other words,
liposomal DOX might be more effective than soluble DOX entering the cells, so the effective intracellular
concentration of DOX could be much higher when liposomal DOX were used. Thereby, to observe a
theoretical synergistic effect of soluble DOX with LT similar to that occurring in LDT, the concentration
of soluble DOX should be much higher. However, when LT were used in combination with soluble
DOX with increasing concentrations of soluble DOX up to a maximum of 1 mM, no cytotoxic effect
was observed, ruling out any synergistic effect of LT with soluble DOX. Moreover, although previous
studies have shown that DOX synergizes with soluble TRAIL to kill cancer cells, inhibition of cell death
by the blocking antibody RIK clearly reflected a pivotal role for TRAIL in LDT-mediated cytotoxicity
and was in agreement with the fact that LD alone had a rather low cytotoxicity. Besides, the data
obtained clearly indicates that the cell death induced by LDT-is a classic caspase-dependent apoptotic
process, relying on TRAIL-mediated caspase-8 activation.
Then, the involvement of the endocytic pathway in LD- and/or LDT-induced cell death was
analyzed, trying to ascertain the mechanism underlying the enhanced cytotoxic effect exhibited by
LDT. In this regard, dynamin-dependent endocytosis has been described to be involved in the cellular
uptake of the liposomal DOX formulation Doxil® [60]. Therefore, we blocked dynamin-dependent
endocytosis by using the specific dynamin inhibitor Dynasore (DYN) [61]. Indeed, DYN was able to
block endocytosis of both liposomal formulations, and especially cell death induced by LDT. Moreover,
both LD and LDT appeared to be internalized in a similar manner and stored at lysosomes, although
with different kinetics. The differences between both liposomal formulations would arise at that point,
where the apoptotic signal triggered by liposomal TRAIL would somehow act in synergy with DOX
located inside the lysosomes. According to this scenario, a situation in which LT were administered in
combination with LD should render a similar outcome to LDT. In fact, although a similar effect could
be obtained by treating the cells with LD and LT in parallel, LDT presents the advantage of assuring
the simultaneous action of both agents (DOX and TRAIL), maximizing the pro-apoptotic efficiency.
Taking the results altogether, the cytotoxicity induced by LDT was caspase-8- and TRAIL-dependent
and involved an endocytosis mechanism dependent of dynamin. The mechanism proposed to explain
the cytotoxic effect of LDT is summarized in Figure 7.
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First, a dynamin-dependent endocytosis of the liposome-encapsulated DOX occurred. In fact,
microscopy and flow cytometry results showed that LD was captured by the cells independently of
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the presence of TRAIL on the liposomal surface. In line with this, the commercial liposomal DOX
formulations used in cancer treatment have been proven to be internalized by dynamin-dependent
mechanisms [60]. Hence, both LD and LDT would end up sequestered in lysosomes after being
endocytosed. It is precisely at this point when the caspase-8 activated by the liposome-displayed
TRAIL would come into action by triggering the lysosomal rupture, facilitating the release of free DOX
to the cytosol, and finally, its translocation to the nucleus, unleashing a potent apoptotic process. In fact,
lysosomal permeabilization by active caspase-8 has already been described in the literature [65–67].
Interestingly, this model is only valid for liposome-displayed TRAIL, since soluble TRAIL did not
show any synergistic effect when administered in parallel with LD (data not shown). This would
highlight the need for a robust caspase-8 activation, which could only be provided by LT or LDT.
Novel liposomal formulation anchoring TRAIL on the surface and encapsulating DOX inside
lumen, that is LDT, exhibited an extraordinary cytotoxic effect against a wide range of tumor types;
however, it was also cytotoxic on freshly isolated PBMC and on activated T lymphocytes. Therefore,
LDT with a concentration of DOX 10 times less than those previously described but with the same
concentration of TRAIL, named LDT 1/10, was also generated in order to diminish LDT toxicity
on normal cells. In fact, LDT 1/10 was not toxic on neither PBMC nor activated T lymphocytes.
These results agree with previous data indicating that neither sTRAIL nor LT induced significant cell
death on T-cells [37,46,68], and demonstrate that LDT with a lower concentration of DOX did not
cause cytotoxic effects on normal cells. However, the reduction of DOX concentration into LDT could
hamper their cytotoxicity against cancer cells. As expected, LDT 1/10 exhibited slightly less cytotoxicity
than LDT, though the reduction was only minute, and all cells were still largely sensitive to the 1/10
version of LDT. All these data, taken together, indicate that optimization of the concentration of DOX
encapsulated inside the liposomal lumen allows it to retain its cytotoxicity against tumor cells but
suppress toxicity for normal cells.
Finally, we wanted to assess the in vivo anti-tumor activity of LDT. First, and before starting any
in vivo approximation, was a possible systemic toxicity exerted by LDT 1/10. In fact, his-tagged sTRAIL
was shown to have a cytotoxic effect on primary human hepatocytes [69,70]. Therefore, a pilot study
was designed seeking to analyze LDT 1/10 in vivo safety. Serum obtained by blood samples from mice
treated with LDT 1/10 was analyzed to determine the levels of aspartate aminotransferase (AST) and
alanine aminotransferase (ALT), clinical markers for liver health, by standard protocols, as previously
described [57]. At the same time, liver, kidney, spleen, and ovaries were also surgically extracted to
perform a histological analysis of any possible tissular damage induced by LDT 1/10. The analysis
of serum levels of the transaminases alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) did not show relevant changes when comparing LDT 1/10 treated mice with control mice.
In addition, the normal tissue architecture was conserved in all tissues analyzed, including hepatic
tissue. No signs of inflammatory infiltrate, fibrosis, or necrosis could be detected in any tissue in mice
treated with LDT 1/10. Therefore, it could be concluded that LDT 1/10 did not induce any systemic
toxicity on any tissue analyzed, validating their use in vivo. Once any systemic toxicity of LDT 1/10
was discarded, their anti-tumor activity was analyzed in an in vivo model using HT1080-xenograft
tumors in nude mice. LDT 1/10 was able to slow down the tumor growth in a significant manner when
compared to untreated animals and most importantly, when compared to LT. These results confirmed
that LDT not only showed high in vitro bioactivity but also a strong in vivo anti-tumor activity.
4. Materials and Methods
4.1. Generation of Different Versions of Lipid Nanoparticles Decorated with TRAIL
Large unilamellar vesicles (LUVs) with soluble TRAIL (sTRAIL) tethered on their surface
(hereafter LT) were generated as previously described [37,57]. Briefly, LUV-type lipid nanoparticles
were generated with the following lipid composition: phosphatidylcholine, sphingomyelin,
cholesterol, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine)-N-(methoxy(polyethylene glycol)-2000)
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(ammonium salt) (18:0 PEG2000-PE), and 1,2-dioleoyl-sn-glycero-3-((N-(5-amino-1-carboxypentyl)
-iminodiacetic acid)succinyl) (nickel salt) (DOGS-NTA-Ni) (Avanti Polar Lipids) with a weight ratio of
50:30:10:5:5. After that, sTRAIL (rTRAIL-His6, corresponding to amino acids 95–281, kindly provided
by Dr. M. MacFarlane [71]) was attached to their surface by incubation at 37 ◦C for 30 minutes.
Large unilamellar vesicles (LUVs) with DOX encapsulated inside their lumen and decorated with
TRAIL on their surface (hereafter LDT, Figure 1a) were synthetized as outlined in the protocol shown
in Figure 1b. The method used for generation of LDT was the pH gradient method [72,73]. First,
LUVs were prepared by using 300 mM (NH4)2SO4 (ammonium sulphate, AS) at pH = 4 to resuspend
the dry lipid film for generating LUV-AS. Once extruded, LUV-AS were filtrated through a PD-10
desalting column (GE Healthcare) to create a pH and ion gradient between the external medium and
the liposomal lumen by exchanging the external buffer to PBS. After that, LUV-AS were incubated with
DOX at a molar drug-to-lipid ratio of 1/3.8 at 60 ◦C for 30 minutes, shaking at 800 rpm for obtaining
LUV with DOX encapsulated inside (LUVDOX, hereafter LD), and then they were incubated with
sTRAIL to obtain LDT. The final concentrations of total lipid, TRAIL, and DOX were 2.5 mM, 12 µg/mL
and 775 µM, respectively. LDT with a concentration of DOX 10 times less than those previously
described (LDT 1/10) was also generated. To assess the encapsulation efficiency of DOX inside the
liposomal lumen, the absorbance of DOX at 480 nM was measured and a calibration curve using free
DOX (concentration range from 0 to 40 µM, Supplementary Figure S1b) was used to finally quantify
the amount of encapsulated DOX. Samples were taken from the reaction mixture at the indicated times
and were subjected to size exclusion filtration through PD-10 desalting columns to capture the free
doxorubicin. The flow through fractions containing the liposomes were collected and lysed in PBS
containing 1% Triton X-100 (Sigma, St. Louis, MS, U.S.) to disrupt the lipid bilayer and release the
entrapped DOX. Absorbance at 480 nm of each fraction was measured. As a negative control, the
encapsulation process was also carried out with classic LUV (containing PBS instead of AS) in parallel.
Once the feasibility and efficiency of DOX encapsulation inside LUV-AS (LUVDOX) was proven,
the next step was to attach sTRAIL on their surface. For that, sTRAIL was incubated with LD at the
same protein/lipid ratio as in the classic LT [37] to obtain the LDT formulation. Since sTRAIL was
coupled to LD incubating at 15 ◦C to diminish a possible DOX leakage, instead of 37 ◦C, as in the
case of classic LT formulation, the efficiency of the TRAIL attachment process was checked to discard
a possible low-binding efficiency. For that, LDT were ultra-centrifuged at 60,000 rpm for 5 hours,
and the presence of uncoupled 25 kD as TRAIL in the supernatant was assessed by Western blot
(Supplementary Figure S1e). The coupling efficiency was very high and similar to that of classic LT [57],
validating the modification of the protocol. Therefore, the final concentration of DOX and TRAIL in
the stock of LDT was 775 µM and 12 µg/mL, respectively.
4.2. Cell Culture
A549 (derived from non-small cell lung carcinoma), HT-29 (derived from colon adenocarcinoma),
RAJI (derived from Burkitt’s lymphoma), U937 (derived from histiocytic lymphoma), MOLT4 (derive
from T-cell acute lymphoblastic leukemia), A673 (derived from Ewing’s sarcoma), HT-1080 (derived
from fibrosarcoma), and RD cells (derived from rhabdomyosarcoma) cell lines were obtained from ATCC.
Cell lines were routinely cultured at 37 ◦C with 5% CO2 in DMEM medium supplemented with 10%
fetal calf serum (FCS), 2 mM L-glutamine, and penicillin/streptomycin (hereafter, complete medium).
Peripheral blood mononuclear cells (PBMC) were obtained from whole peripheral blood samples
from healthy donors by density gradient centrifugation using Ficoll-Paque® (GE Healthcare). T-cell
blasts were generated by stimulating PBMC (2× 106 cells/mL) with 5 µg/mL PHA (phytohemagglutinin)
for 1 day. Then, PHA was removed, and cells were resuspended in complete medium supplemented
with 30 UI/mL IL-2 and cultured for 6 days changing medium every 48 h.
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4.3. Cytotoxicity Assays and Apoptosis Quantification
Tumor cell lines (3 × 104 cells) were treated with LT and LDT for 24 hours at the following
concentrations: 1, 4, 12, 37, 11, 333, and 1000 ng/mL of TRAIL, which corresponded to the following
concentrations of DOX: 0.09, 0.27, 0.8, 2.39, 7.17, 21.52, and 64.56 µM, respectively. Dose-response
experiments were also performed using LDT with the same concentration of TRAIL, but with a
concentration of DOX 10 times less than those previously indicated (LDT 1/10). LUV-type liposomes
without TRAIL anchored to their surface but loaded with DOX (LD and LD 1/10) with the previously
described doses were also used in cytotoxicity assays. Time-course experiments were also carried
out incubating the epithelial-derived cancer cell lines A549, SKBR3, and HT-29 and the sarcoma cell
lines A673, HT-1080, and RD with 1000 ng/mL of LT, LD, and LDT for 1, 2, 4, and 6 hours. Times of
incubation at 8 and 20 hours were also included for sarcoma cells. Experiments of apoptosis inhibition
assays were carried out by pre-incubating cells with the blocking anti-human TRAIL mAb (500 ng/mL,
clone RIK2, BD Biosciences), with the pan-caspase inhibitor z-VAD-fmk (30 µM, Bachem, Bubendorf
BL, Switzerland) or with the specific caspase-o inhibitor IETD-fmk (30 µM, Bachem) for 1 hour prior to
the addition of LT or LDT. Finally, apoptosis induced by different liposome formulations was analyzed
by annexin-V staining using a FACSCalibur flow cytometer and CellQuest software (BD Biosciences).
4.4. Scanning Electron Microscopy
Samples of LDT for analysis by SEM were prepared as previously described [57]. Briefly,
after adding glutaraldehyde to bare LDT suspensions up to a final concentration of 1%, a drop
was placed onto a glass microscope slide previously treated with 3-aminopropyltriethoxysilane (Sigma).
Then, the sample was washed with PBS, fixed with 1% OsO4, and washed again with PBS. Thereafter,
the sample was dehydrated in a graded series of ethanol (25%–100%), mounted on specimen, and
coated with gold. Finally, the sample was analyzed using a Hitachi S-3400 N scanning electron
microscope (Hitachi, Tokyo, Japan).
4.5. Western Blot Analysis
Western blot was performed for protein expression analysis, as previously described [47–49].
The antibodies used to analyze the expression of the main proteins involved in the apoptotic pathway
were: anti-caspase-8 (BD Biosciences), anti-caspase-3 (Cell Signaling), anti-Bid (BD Biosciences),
anti-PARP-1 (BD Biosciences), and anti-caspase-9 (MBL). The expression of β-actin was analyzed as
loading control, using a specific antibody (Sigma). Western blot was also carried out to assess the
binding of TRAIL to LD using the anti-TRAIL antibody RIK2 (eBiosciencies).
For Western blot analysis, cells (5 × 106) were lysed at 4 ◦C with 100 µL of a buffer containing 1%
Triton X-100 and protease and phosphatase inhibitors, as previously described [46–49]. Then, protein
from lysed cells were separated by 12% SDS-PAGE, transferred to PVDF membranes, and blocked with
TBS-T buffer (10 mM Tris/HCl, pH 8.0, 0.12 M NaCl, 0.1% Tween-20, 0.05% sodium azide) containing
5% skimmed milk. PVDF membranes were incubated with the above-mentioned antibodies in TBS-T
containing 2% skimmed milk. After that, PVDF membranes were washed with TBS-T, incubated with
0.2 µg/mL of peroxidase-labeled or phosphatase alkaline-labeled secondary antibody (Sigma), and
revealed with the corresponding substrate Pierce ECL Western Blotting Substrate (Thermo Scientific,
Waltham, MA, U.S.) or CDP-Star (Merck, Kenilworth, New Jersey, U.S.), respectively.
4.6. Fluorescence Microscopy Analysis
Analysis of the intracellular location of liposome formulation were performed by fluorescence
microscopy. For that, A549 cells were pre-treated for 1 h with Lysotracker™ green (ThermoFisher).
Then, cells were treated with LD or LDT at their maximum working concentrations (1000 ng/mL
TRAIL; 64.56 µM DOX) for 1 hour. At the final time, medium was carefully replaced, and cells were
cooled for 10 min at 4 ◦C. Finally, green fluorescence corresponding to lysosomal compartment and red
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fluorescence corresponding to DOX were photographed using a fluorescence microscopy (E600/E400,
Nikon, Tokyo, Japan) equipped with a digital photograph system (DXM 1200F, Nikon).
4.7. Confocal Fluorescence Microscopy Analysis
For analysis of LD and LDT by confocal microscopy, A549 cells were seeded in 8-well chamber
slides (Labtek®, 20 × 104 cells per condition). The following day, cells were treated for the indicated
times with LD or LDT. At the end of the treatment, slides were quickly washed with cold PBS and
fixed in PFA 4% for 30 minutes at room temperature in the dark. Next, cells were blocked with
PBS 5% FCS, and then they were stained overnight with an anti-LAMP1 antibody (Cell Signaling).
The following day, cells were washed and incubated with an Alexa 488 secondary antibody. Finally,
cells were washed, and mounted onto drops of Fluoromount-G (Southern Biotech) containing DAPI.
Fluorescence images were taken using a confocal microscopy (Olympus FV10i). Data was analyzed
using a FV10-ASW Viewer, v3.1 (Olympus).
4.8. Study of the Internalization Mechanism
To analyze the endocytic pathways involved in LT-induced signaling, Dynasore (DYN, Sigma), a
small molecule GTPase inhibitor that targets dynamin-1, -2, and Drp1, was used [61]. The cell lines A549,
HT-29, and SKBR3 were incubated in the presence or absence of DYN (80 µM) for 1 hour. After that,
cells were treated with LD or LDT at 1000 ng/mL for 3 hours. Experiments pre-incubating cells with
the caspase-8 inhibitor z-IETD-fmk (30 µM) for 1 hour prior to addition of liposome formulations were
also performed. Finally, apoptosis was quantified by annexin-V staining. Doxorubicin uptake was
measured quantifying the mean fluorescence intensity (MFI) at the FL3 channel (red fluorescence).
Both annexin-V staining and DOX MFI were analyzed using a FACSCalibur flow cytometer and
CellQuest software (BD Biosciences).
4.9. In Vivo Study of Toxicity
Immune-deficient athymic mice, Hsd:Athymic Nude-Foxn1nu, six-week-old females (Janvier),
were used to evaluate in vivo toxicity. All experiments in mice were carried out according to the
European recommendations on animal ethics and were approved by the University of Zaragoza Animal
Experimentation Ethical Committee (PI 18/16).
In order to assess the toxicity of LDT, five animals were systemically injected with 36 µg of LDT 1/10
4 times with an interval of 2 days between each injection. Control mice (2 animals) were injected with
PBS. After 2 weeks, mice were sacrificed and blood was collected by heart puncture, and serum was
obtained from them by centrifugation and stored at −20 ◦C until analysis. Aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) serum levels were determined as previously described [48,57].
At the same time, mice were sacrificed, and liver, kidney, spleen, and ovaries were surgically dissected
and fixed in 10% buffered formalin. After fixation for three days, tissues were embedded in paraffin
and sectioned in 5 µm sections. The slides were then deparafined in xylene, dehydrated in a gradient
of alcohols, and stained using hematoxylin and eosin (H and E).
4.10. In Vivo Anti-Tumor Activity
Same immune-deficient athymic mice as above mentioned (Hsd:Athymic Nude-Foxn1nu, six-week
old females), were used to evaluate in vivo antitumor activity. As previously mentioned, all experiments
in mice were performed following the European recommendations on animal ethics and were approved
by the University of Zaragoza Animal Experimentation Ethical Committee (PI 18/16). Mice were kept
under specific standard pathogen-free conditions throughout the study.
Freshly harvested H-1080 cells (5 × 106 cells/mouse) were inoculated subcutaneously into mice.
Once tumors reached a volume of 100 mm3, mice were randomly divided in 3 groups: Control (4 mice),
LT (6 mice), and LDT (6 mice). 36 µg of TRAIL as LT or LDT 1/10, in a total volume of 200 µL, were
injected intra-peritoneally daily during 4 consecutive days. The Control group were injected with
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sterile PBS. Tumors were left to grow until they reached 1000 mm3 or when clinical signs required
euthanasia. During all of the experiments, tumor volumes were monitored daily, and tumor volume
was calculated using the following formula: tumor volume = L ×W × H (where L is length, W is
width, and H is the height dimensions of the tumor, respectively).
4.11. Statistical Analysis
Computer-based statistical analysis was carried out using the Prism® software program (GraphPad
Software, San Diego, CA, U.S.). All values are expressed as mean ± standard deviation (SD) of at
least 3 experiments. Statistical significance was analyzed by using Student’s t-test. A p < 0.05 was
considered statistically significant.
5. Conclusions
Doxorubicin (DOX) has been widely described to synergize with sTRAIL when administered in
combination. In this line, nanoparticles combining both molecules have already been developed [38,74–77].
Consequently, the generation of a unique formulation that includes both anti-cancer drugs, such as
LUVDOX-TRAIL, could be of great interest to treat different types of cancer. Our liposomal formulation
shows a cytotoxic potential and a synergy never observed in any TRAIL and DOX combination before.
In summary, LDT exerted an enhanced anti-tumor effect not only in vitro but also in vivo without
overt adverse effects and could potentially be clinically relevant to improve anti-tumor therapy against
TRAIL-resistant cancers.
6. Patents
Alberto Anel and Luis Martinez-Lostao have filed a patent application (W02011020933) for the
use of liposome-bound Apo2L/TRAIL.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/12/1948/s1,
Figure S1: Cytotoxicity of soluble TRAIL on a panel of tumor cell lines from distinct origin, Figure S2: Cytotoxicity
of LUV-DOXTRAIL on HCT-116 Bax-/-shBak, RH4 cells and SKBR3 siCASP8 cells, Figure S3: Cytotoxicity of
LUVDOX-TRAIL 1/10 on peripheral blood mononuclear cells and T-cell basts.
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